Compliance in an Outsource Manufacturing Model: What to Look For - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Compliance in an Outsource Manufacturing Model: What to Look For
The authors provide detailed lists of important checkpoints to consider when selecting an outsourcing provider.


Pharmaceutical Technology


Additional questions

  • If a stability program exists, are there adequate policies, procedures, and study protocols?
  • Are storage areas sized and organized to prevent mix-ups? Is general housekeeping neat and orderly?
  • Do written procedures identify storage time beyond which components, containers, and closures must be reexamined before use?
  • Are all materials handled in such a way to prevent contamination and mix-ups?
  • Are materials spaced to allow for cleaning and inspection?
  • Are rejected components, material, and containers quarantined and clearly marked to prevent their use?

Conclusion

During the course of routine production, and as governed by the quality agreement, the sponsor will perform routine audits to ensure continued compliance. With a solid baseline established during the selection phase, the sponsor can then focus on areas where risk to product quality is highest. By properly selecting, evaluating, and monitoring a third-party supplier, the sponsor can ensure continued compliance over the longterm.

Tim Keutzer* is the director of project management at Cubist Pharmaceuticals, 65 Hayden Ave., Lexington, MA 02421, tel. 781.860.8331, fax 781.860.1131,
. Howard Silver is the manager of GMP compliance at Cubist Pharmaceuticals.

*To whom all correspondence should be addressed.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here